Response Biomedical Corporation (Response), a Canada based medical devices company, has reported preliminary revenues for the first quarter of fiscal 2009. For the period, the company reported revenues of CAD2.526 million, up 115%, compared with CAD1.173 million for the year-ago quarter.
Complete first quarter 2009 unaudited interim financial results are anticipated to be released on May 15, 2009.
“Our exceptional performance this quarter shows that our strategy is working,” said S. Wayne Kay, chief executive officer, Response. “Our blue-chip partners are placing orders to support the launch of our infectious diseases and cardiovascular products into the U.S. and we are developing new alliances, such as the one announced last month with FIND, for additional uses of our technology platform. We are pleased that our revenues in the first quarter of 2009 are in line with our expectations and we anticipate continued strong year-over-year revenue growth as we move towards profitability. We believe that these results will be of great assistance in our efforts to address our current financing needs. Our success is due to the tireless and outstanding work of our employees and the steadfast commitment of our partners.”